发热伴血小板减少综合征研究热点的可视化分析

[摘要]　目的　对发热伴血小板减少综合征（severe fever with thrombocytopenia syndrome, SFTS）的相关文献进行文献计量学和可视化分析，探寻近年来的研究现状、热点及趋势，为临床治疗和基础研究提供参考。方法?以Web of Science（WOS）核心合集和中国知网（China national knowledge infrastructure, CNKI）数据库为文献来源，检索2011年1月1日—2021年12月31日有关SFTS的文献，导入CiteSpace.5.7.R2软件，以国家、作者、文献共被引、关键词为节点进行可视化分析，并绘制相关图谱。结果?在WOS核心合集共检索到797篇文献，在CNKI数据库共检索到714篇文献。相关领域发文量总体呈上升趋势，中国发文量居首位，美国和日本之间机构合作密切。研究热点集中在发病机制、抗体、特异性治疗等领域。非结构蛋白、临床预后、血小板减少、SFTS感染的靶细胞等将是未来的研究重点。结论?国内外关于SFTS的研究逐渐成熟，新型布尼亚病毒、免疫功能、预后是研究重点，但是对SFTS发病机制和病毒受体尚不清楚，仍须进一步探索。     

Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies

PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies.     

社区严重精神障碍患者规律面访情况及其影响因素研究

背景严重精神障碍患者因自知力欠缺及高复发性、高致残性等特点，对社会稳定造成严重威胁。做好社区面访管理工作意义重大，通过定期面访患者本人，可以更好地综合评估患者病情，以便及时采取措施，提高管理服务质量。目的了解社区严重精神障碍患者规律面访情况及其影响因素，为提高社区患者的面访服务管理质量提供参考依据。方法2020年10—12月，利用2019年底江苏省严重精神障碍管理系统中建档管理的无锡市严重精神障碍患者基础档案及随访管理信息，分析当年度无锡市社区严重精神障碍患者规律面访情况，采用Logistic回归分析规律面访的影响因素。结果共纳入27 778例研究对象，其规律面访率为81.08%（22 523/27 778）。Logistic回归分析结果显示，非本地户籍〔OR（95%CI）=0.704（0.640，0.775）〕、年龄≤44岁〔OR（95%CI）=0.522（0.472，0.578）〕、学历为高中及以上〔高中/中专OR（95%CI）=0.493（0.446，0.545），大专及以上OR（95%CI）=0.470（0.415，0.532）〕、目前有正式工作〔OR（95%CI）=0.715（0.668，0.766）〕、未婚〔OR（95%CI）=0.746（0.665，0.838）〕、经济状况为非贫困〔OR（95%CI）=0.587（0.517，0.666）〕、没有进行抗精神病药物治疗〔OR（95%CI）=0.491（0.440，0.548）〕、服药时长0~10年〔OR（95%CI）=0.881（0.778，0.998）〕、不是"以奖代补"监护补助对象〔OR（95%CI）=0.807（0.704，0.926）〕、不参加社区康复服务〔OR（95%CI）=0.844（0.716，0.996）〕是患者规律面访的消极影响因素（P<0.05）。结论无锡市社区严重精神障碍患者规律面访率尚需进一步提高，应重点关注非本地户籍、年龄≤44岁、高中及以上学历、目前有正式工作、未婚、经济非贫困、没有进行抗精神病药物治疗、服药时长0~10年、不是监护补助对象和不参加社区康复服务的社区严重精神障碍患者。可通过制定倾斜性政策、开展宣传教育、降低患者病耻感、改善患者疾病认知、加强患者社会支持等措施提高患者规律面访率。     

发热伴血小板减少综合征研究热点的可视化分析

[摘要]　目的　对发热伴血小板减少综合征（severe fever with thrombocytopenia syndrome, SFTS）的相关文献进行文献计量学和可视化分析，探寻近年来的研究现状、热点及趋势，为临床治疗和基础研究提供参考。方法?以Web of Science（WOS）核心合集和中国知网（China national knowledge infrastructure, CNKI）数据库为文献来源，检索2011年1月1日—2021年12月31日有关SFTS的文献，导入CiteSpace.5.7.R2软件，以国家、作者、文献共被引、关键词为节点进行可视化分析，并绘制相关图谱。结果?在WOS核心合集共检索到797篇文献，在CNKI数据库共检索到714篇文献。相关领域发文量总体呈上升趋势，中国发文量居首位，美国和日本之间机构合作密切。研究热点集中在发病机制、抗体、特异性治疗等领域。非结构蛋白、临床预后、血小板减少、SFTS感染的靶细胞等将是未来的研究重点。结论?国内外关于SFTS的研究逐渐成熟，新型布尼亚病毒、免疫功能、预后是研究重点，但是对SFTS发病机制和病毒受体尚不清楚，仍须进一步探索。     

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial

BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110.     

Organization of the 43rd European Congress of Cytology in the SARS–CoV-2 pandemic period: A report

The 43rd European Congress of Cytology in Wrocław, Poland, was held as a hybrid meeting in the Fall of 2021. After nearly 2 years without in-person cytology conferences, the 43rd Congress represents 1 of the first major international scientific meetings to occur during the severe acute respiratory syndrome-coronavirus 2 pandemic. Since March 2020, the pandemic situation substantially modified the organization of scientific meetings because of both domestic and international travel restrictions, new health standards, and concern among participants, resulting in new alternative forms of virtual conferencing. Cancer (Cancer Cytopathol) 2022;130:000-000. ;     

原发性免疫缺陷病和脊髓性肌萎缩症临床特点及新生儿早期联合筛查实践

原发性免疫缺陷病(PID)及脊髓性肌萎缩症(SMA)均是由基因突变引起的能严重影响儿童健康甚至导致死亡的遗传性出生缺陷,早期发现和及时诊断治疗是影响预后的关键,新生儿筛查是目前实现早期诊断和干预的有效手段。近年来部分国家和地区已将SMA和PID中最为严重的重症联合免疫缺陷病(SCID)和最常见的B细胞缺乏症X连锁无丙种球蛋白血症(XLA)纳入新生儿筛查范围。浙江省在国内首次开展对SCID、XLA和SMA三种遗传性疾病的新生儿早期联合筛查实践,极大地提高了筛查效率,使出生缺陷三级预防关口前移,有助于显著改善患者的预后、提高生活质量、降低死亡率。     

Organoids in modelling infectious diseases

Approaches based on animal and two-dimensional (2D) cell culture models cannot ensure reliable results in modeling novel pathogens or in drug testing in the short term; therefore, there is rising interest in platforms such as organoids. To develop a toolbox that can be used successfully to overcome current issues in modeling various infections, it is essential to provide a framework of recent achievements in applying organoids. Organoids have been used to study viruses, bacteria, and protists that cause, for example, respiratory, gastrointestinal, and liver diseases. Their future as models of infection will be associated with improvements in system complexity, including abilities to model tissue structure, a dynamic microenvironment, and coinfection.Teaser.Organoids are a flexible tool for modelling viral, bacterial and protist infections. They can provide fast and reliable information on the biology of pathogens and in drug screening, and thus have become essential in combatting emerging infectious diseases.     

北京市精神卫生医务人员对严重精神障碍发病报告制度的认知研究

背景 严重精神障碍发病报告制度作为精神卫生监测的重要一环已运行实施多年，实施效果需要进一步探知。 目的 分析北京市三类精神卫生医务人员对严重精神障碍发病报告制度重要性、主要作用、实施效果、存在问题及完善措施的认知，为促进该制度的完善提供建议。 方法 2019年3—6月，采用方便抽样方法选择234例市级精神专科医院医务人员，采用分层抽样方法选择183例区级精神专科医院医务人员，采用分层抽样方法选择214例社区精神卫生防治医务人员作为研究对象，采用"北京市精神卫生法治状况调查问卷"进行问卷调查，问卷主要内容包括医务人员基本信息及对严重精神障碍发病报告制度的认知。 结果 对于制度重要性，56.3%（103/183）的区级精神专科医院和54.7%（117/214）的社区精神卫生防治医务人员认为其"非常重要"，66.7%（156/234）的市级精神专科医院医务人员认为其"比较重要"。对于主要作用，76.9%（180/234）的市级精神专科医院医务人员和82.7%（177/214）的社区精神卫生防治医务人员认为该制度主要作用为"风险预警"，80.9%（148/183）的区级精神专科医院医务人员认为该制度主要作用为"社区管理"。对于实施效果，44.4%（104/234）的市级精神专科医院医务人员、50.3%（92/183）的区级精神专科医院医务人员和50.9%（109/214）的社区精神卫生防治医务人员认为严重精神障碍发病报告制度实施效果比较好。对于存在问题，77.8%（182/234）的市级精神专科医院医务人员、78.1%（143/183）的区级精神专科医院医务人员和83.2%（178/214）的社区精神卫生防治医务人员认为该制度主要存在的问题为"报告涉及患者隐私信息的收集"。对于完善措施，73.5%（172/234）的市级精神专科医院医务人员和76.6%（164/214）的社区精神卫生防治医务人员认为严重精神障碍发病报告制度完善措施为"规范信息录入、登记、更正、汇总制度"，68.9%（126/183）的区级精神专科医院医务人员认为制度完善措施为"规范信息共享及对患者隐私保护的制度"。 结论 三类医务人员对严重精神障碍发病报告制度的作用及实施效果表示肯定，为实现风险防控与隐私保护并重，兼顾患者管理与服务，应当对该制度予以完善，包括：在法律层面细化相关规定；对患者坚持服务保障与管理并重，完善精神卫生服务体系，落实基本与重大公共卫生服务项目；增加政策宣传力度，提高患者及家属对该制度的认可度。